机构:NYU, Sch Med, Smilow Res Ctr, Div Nephrol, New York, NY 10016 USA
Albaqumi, Mamdouh
Soos, Timothy J.
论文数: 0引用数: 0
h-index: 0
机构:NYU, Sch Med, Smilow Res Ctr, Div Nephrol, New York, NY 10016 USA
Soos, Timothy J.
Barisoni, Laura
论文数: 0引用数: 0
h-index: 0
机构:NYU, Sch Med, Smilow Res Ctr, Div Nephrol, New York, NY 10016 USA
Barisoni, Laura
Nelson, Peter J.
论文数: 0引用数: 0
h-index: 0
机构:NYU, Sch Med, Smilow Res Ctr, Div Nephrol, New York, NY 10016 USA
Nelson, Peter J.
机构:
[1] NYU, Sch Med, Smilow Res Ctr, Div Nephrol, New York, NY 10016 USA
[2] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA
来源:
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
|
2006年
/
17卷
/
10期
关键词:
D O I:
10.1681/ASN.2006030225
中图分类号:
R5 [内科学];
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号:
1002 ;
100201 ;
摘要:
Collapsing glomerulopathy (CG) has become an important cause of ESRD. First delineated from other proteinuric glomerular lesions in the 1980s, CG is now recognized as a common, distinct pattern of proliferative parenchymal injury that portends a rapid loss of renal function and poor responses to empiric therapy. Notwithstanding, the rise in disorders that are associated with CG, the identification of the first susceptibility genes for CG, the remarkable increase in murine modeling of CG, and promising preclinical testing of new therapeutic strategies suggest that the outlook for CG as a poorly understood and therapeutically resistant renal disease is set to change in the future. This focused review highlights recent advances in research into the pathogenesis and treatment of CG.